There are currently 54 active clinical trials seeking participants for Chronic Kidney Diseases research studies. The states with the highest number of trials for Chronic Kidney Diseases participants are California, Texas, Florida and New York.
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama +97 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)
Recruiting
This pilot study will assess the efficacy of a pregnancy and contraception education decision aid (DA) for patients with chronic kidney disease to support decisions about reproductive health, and will assess feasibility and acceptability of the intervention to inform future Research Project Grant (R01) level studies.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/10/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: CKD, Chronic Kidney Diseases
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
04/09/2025
Locations: Paradise Clinical Research Group LLC, Glendora, California +65 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
Recruiting
The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes, Chronic Kidney Diseases
Chronic Kidney Disease-Education (CKD-EDU)
Recruiting
The investigators are conducting a study to see which program better helps older patients with kidney disease choose their treatment. Investigators are also investigating if either program can reduce the number of hospital or emergency room visits in the first 6 months of the study, as well as potentially improve end-of-life care for older adults. Half of the participants will receive Program A, while the other half will receive Program B. Investigators will compare the two groups to see which... Read More
Gender:
ALL
Ages:
75 years and above
Trial Updated:
04/02/2025
Locations: UR Medicine Nephrology - Strong West, Brockport, New York +4 locations
Conditions: Chronic Kidney Diseases
Sit Less, Interact and Move More (SLIMM) 2 Study
Recruiting
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Theref... Read More
Gender:
ALL
Ages:
20 years and above
Trial Updated:
03/28/2025
Locations: Stanford University, Stanford, California +1 locations
Conditions: Chronic Kidney Diseases, Obesity
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Recruiting
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/26/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Recruiting
This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: AKDHC Bullhead City, Bullhead City, Arizona +21 locations
Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
APOL1 Genetic Testing Program for Living Donors
Recruiting
Living donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves. African American (AA) LDs have an even greater, 3.3-fold, risk of ESKD than white LDs post-donation. Because evidence suggests that Apolipoprotein L1 (APOL1) risk variants contribute to this greater risk, transplant nephrologists are increasingly using APOL1 testing to evaluate LD candidates of African ancestry. However... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Medstar Georgetown Transplant Institute, Washington, District of Columbia +1 locations
Conditions: Chronic Kidney Diseases, Apolipoprotein L1, Kidney Transplantation
Kidney Health: Eat Well, Live Well
Recruiting
This two-arm, parallel randomized trial study will assess the efficacy of a 6-month (26 weeks) community-based program in reducing kidney injury (as Urine Albumin to Creatinine ratio, uACR), cardiovascular risk (as Hemoglobin A1C and blood pressure), mental health (as PHQ-8) and diet quality (as fruits and vegetables intake and Healthy Eating Index) in community-dwelling, low-income adults diagnosed with early chronic kidney disease (stages 2 or 3 and not on kidney replacement therapies) compare... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Harris Health System's Outpatient Center, Houston, Texas +2 locations
Conditions: Chronic Kidney Diseases
American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)
Recruiting
Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascula... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
03/24/2025
Locations: NIDDK-Phoenix Epidemiology and Clinical Research, Phoenix, Arizona +2 locations
Conditions: Diabetes Mellitus, Chronic Kidney Diseases, Heart Diseases, Cardiovascular Diseases
APOL1 Genetic Testing in African Americans
Recruiting
Recent breakthroughs in medical genetics have discovered that a portion of kidney failure affecting the Black community is mediated by coding variants in a gene called apolipoprotein L1 (APOL1) - and that genetic variants, not race - account for increased risk. For APOL1 genetic testing to be applied in a manner that improves patient care and outcomes, more information is needed regarding associations of genotype with clinical parameters related to kidney health. Further, understanding patient p... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/17/2025
Locations: SSM Health Saint Louis University Hospital, Saint Louis, Missouri
Conditions: Genetic Predisposition, Chronic Kidney Diseases, Nephropathy, APOL1 Associated Kidney Disease, Disparities